Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in relapsed or refractory systemic ALCL
NCT00866047Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Mar 2009
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Anaplastic Large Cell Lymphoma (ALCL), sponsored by Seagen Inc. Primary endpoint: Objective Response Rate by Independent Review Group at 12 months. Started Mar 2009; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Anaplastic Large Cell Lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00866047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866047.